---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-157911"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:21:10.466309+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024

## Summary
- Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.
- Metzger is CEO of Syndax Pharmaceuticals (Nasdaq: SNDX) and has over 25 years biopharma experience.
- He will serve on Audit and Compensation Committees; received stock options for 70,683 shares vesting over three years.
- Board determined Metzger qualifies as independent director under Nasdaq standards.

## SEC filing metadata
- accession: 0001193125-24-157911
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/0001193125-24-157911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/d843596d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-157911
- JSON: https://secwatch.observer/filing/0001193125-24-157911.json
- Plain text: https://secwatch.observer/filing/0001193125-24-157911.txt

## Key facts
- Executive change
  Michael A. Metzger was appointed as Director at Pyxis Oncology, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/0001193125-24-157911-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.